Tyme (TYME) 10-Q 9 Aug 22 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Jun. 30, 2022	Aug. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Trading Symbol	TYME
Entity Registrant Name	TYME TECHNOLOGIES, INC.
Entity Central Index Key	0001537917
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		172,206,894
Entity Address, Address Line One	1 Pluckemin Way – Suite 103
Entity Address, City or Town	Bedminster
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07921
City Area Code	212
Local Phone Number	461-2315
Entity Shell Company	false
Entity File Number	001-38169
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-3864597
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, $0.0001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Current Assets
Cash and cash equivalents	$ 6,415,058	$ 13,738,931
Marketable securities	70,690,123	60,611,961
Prepaid clinical costs	431,477	480,623
Prepaid expenses and other current assets	1,483,019	4,064,770
Total current assets	79,019,677	78,896,285
Operating lease right-of-use asset	28,210	38,229
Marketable securities	1,113,824	9,080,671
Total assets	80,161,711	88,015,185
Current liabilities
Accounts payable and other current liabilities (including $0 and $153,000 of related party accounts payable, respectively)	4,685,216	3,803,427
Severance payable	444,472	2,611,857
Accrued bonuses	465,133	933,082
Operating lease liability	26,488	37,332
Total current liabilities	5,621,309	7,385,698
Long-term liabilities
Severance payable, net of current portion	311,370	421,575
Warrant liability	89,559	124,480
Total liabilities	6,022,238	7,931,753
Commitments and contingencies (see Note 9)
Stockholders' equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 172,206,894 issued and outstanding at June 30, 2022, 300,000,000 authorized, 172,206,894 issued and outstanding at March 31, 2022	17,223	17,223
Additional paid in capital	241,571,007	241,030,535
Accumulated other comprehensive loss	(533,762)	(544,264)
Accumulated deficit	(166,914,995)	(160,420,062)
Total stockholders' equity	74,139,473	80,083,432
Total liabilities and stockholders' equity	$ 80,161,711	$ 88,015,185

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	172,206,894	172,206,894
Common stock, outstanding	172,206,894	172,206,894
Drinker, Biddle & Reath LLP ("DBR") [Member]
Related party accounts payable	$ 0	$ 153,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Revenues	$ 0	$ 0
Operating expenses:
Research and development	1,960,753	4,184,411
General and administrative (including $0 and $115,000 of related party legal expenses, respectively)	4,646,637	2,468,159
Total operating expenses	6,607,390	6,652,570
Loss from operations	(6,607,390)	(6,652,570)
Other income (expense):
Change in fair value of warrant liability	34,921	725,143
Other income	89,409	19,523
Interest expense	(11,873)	(21,259)
Total other income (expense)	112,457	723,407
Net loss	$ (6,494,933)	$ (5,929,163)
Basic loss per common share	$ (0.04)	$ (0.03)
Diluted loss per common share	$ (0.04)	$ (0.03)
Basic weighted average shares outstanding	172,206,894	172,205,452
Diluted weighted average shares outstanding	172,206,894	172,205,452
Statements of Comprehensive Loss
Net loss	$ (6,494,933)	$ (5,929,163)
Other comprehensive loss
Unrealized gain (loss) on marketable securities, net of tax	10,502	(33,842)
Comprehensive loss	$ (6,484,431)	$ (5,963,005)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Related party legal expenses	$ 0	$ 115,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance, at beginning at Mar. 31, 2021	$ 101,795,649	$ 17,222	$ 238,572,442	$ (136,794,015)
Balance, at beginning (in shares) at Mar. 31, 2021		172,200,644
Proceeds from the exercise of stock options	6,188	$ 1	6,187
Proceeds from the exercise of stock options (in shares)		6,250
Stock based compensation	643,665		643,665
Unrealized gain (loss) on available-for-sale securities	(33,842)				$ (33,842)
Net loss	(5,929,163)			(5,929,163)
Balance, at end at Jun. 30, 2021	96,482,497	$ 17,223	239,222,294	(142,723,178)	(33,842)
Balance, at end (in shares) at Jun. 30, 2021		172,206,894
Balance, at beginning at Mar. 31, 2022	$ 80,083,432	$ 17,223	241,030,535	(160,420,062)	(544,264)
Balance, at beginning (in shares) at Mar. 31, 2022	172,206,894	172,206,894
Stock based compensation	$ 540,472		540,472
Unrealized gain (loss) on available-for-sale securities	10,502				10,502
Net loss	(6,494,933)			(6,494,933)
Balance, at end at Jun. 30, 2022	$ 74,139,473	$ 17,223	$ 241,571,007	$ (166,914,995)	$ (533,762)
Balance, at end (in shares) at Jun. 30, 2022	172,206,894	172,206,894

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net loss	$ (6,494,933)	$ (5,929,163)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of employees, directors and consultants stock options	540,472	643,665
Change in fair value of warrant liability	(34,921)	(725,143)
Net amortization of premiums and discounts on marketable securities	389,117	227,303
Change in operating assets and liabilities:
Prepaid clinical costs	49,146	905,297
Prepaid expenses and other assets	2,634,261	186,635
Operating lease right-of-use asset	10,019	8,912
Accounts payable and other current liabilities	881,789	(280,959)
Severance payable	(2,277,590)	(167,999)
Accrued bonuses	(467,949)	(670,110)
Operating lease liability	(10,844)	(7,775)
Net cash used in operating activities	(4,781,433)	(5,809,337)
Cash flows from investing activities
Purchases of marketable securities	(17,018,440)	(65,254,424)
Proceeds from maturities of marketable securities	14,476,000
Net cash used in investing activities	(2,542,440)	(65,254,424)
Cash flows from financing activities
Proceeds from exercise of stock options		6,188
Net cash provided by financing activities		6,188
Net decrease in cash and cash equivalents	(7,323,873)	(71,057,573)
Cash and cash equivalents – beginning	13,738,931	107,516,420
Cash and cash equivalents – ending	6,415,058	36,458,847
Supplemental Cash Flow Information:
Interest	$ 11,873	$ 21,259

Nature of Business

Nature of Business	3 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of Business Tyme Technologies, Inc. is a Delaware corporation headquartered in Bedminster, New Jersey, with a wholly owned subsidiary, Tyme Inc. (together, “TYME” or the “Company”). The majority of the Company’s research, development and other business activities are conducted by Tyme Inc., which was incorporated in Delaware in 2013. TYME is an emerging biotechnology company developing CMBTs that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic requirements to cause cancer cell death. The Company has been focused on developing its novel compound, SM-88 and its preclinical pipeline of novel CMBT TM Ongoing Studies OASIS Trial in metastatic HR+/HER2- breast cancer The Company is collaborating with Georgetown University to support a Phase II trial, OASIS, for SM-88 in patients with metastatic breast cancer who have HR+ and HER2- disease (“HR+/HER2-”). This represents approximately 68% of the annual breast cancer diagnoses in the US each year. The OASIS trial is an investigator-initiated prospective open-label Phase II trial evaluating the efficacy and safety of SM-88 with MPS for the treatment of metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor. This trial is designed as a two-stage trial, enrolling up to 50 patients who have failed or progressed after receiving two hormonal agents and a CDK4/6 inhibitor HoPES Trial in sarcoma In early 2020, the open-label Phase 2 investigator-sponsored trial of SM-88 therapy in sarcoma, HoPES, opened. This trial has two cohorts, each expecting to enroll 12 patients. The first is SM-88 with MPS as salvage treatment in patients with mixed rare sarcomas, and the other is SM-88 with MPS as maintenance treatment for patients with metastatic Ewing’s sarcoma who had not progressed on prior therapy. The primary objectives are to measure ORR and PFS. Secondary objectives include DOR, OS, CBR using RECIST, and incidence of treatment-emergent AEs. The Joseph Ahmed Foundation is sponsoring this trial, which is being conducted by PI Dr. Chawla at the Sarcoma Oncology Center in Santa Monica, CA. Preclinical Pipeline Programs In fiscal year 2022, the Company began a comprehensive translational preclinical program focused on SM-88 MOA and Biomarker Identification/Validation. We engaged Evotec, a leading global research and development company, to aid in the execution of these activities and we are also incorporating several complementary academic collaborations into this multi-faceted program. The overall goal of these activities is to potentially identify actionable biomarkers of sensitivity and activity to SM-88 in various cancers, complementary combination drugs strategies for SM-88, and other cancer metabolism targets that could benefit from treatment. TYME-18 is a CMBT TM TYME-19 is an oral synthetic member of the bile acid family. The Company also uses bile acids in its anti-cancer drug candidate, TYME-18. Because of its expertise in bile acids and their effects, the Company was able to identify TYME-19 as a well-characterized bile acid with potential antiviral properties. Bile acids have primarily been used for liver disease; however, like all steroids, they are messenger molecules that modulate a number of diverse critical cellular processes. Bile acids can modulate lipid and glucose metabolism and can remediate dysregulated protein folding, with potentially therapeutic effects on cardiovascular, neurologic, immune, and other metabolic systems. Some agents in this class have also previously shown antiviral properties. The Company retained virology experts at Evotec to assess the mechanisms of TYME-19. Evotec is a global drug development company that has the capability to access the multiple existing and emerging variants of the COVID-19 virus. TYME and Evotec have tested the ability of TYME-19 to interrupt the cellular pathways commonly used by viruses to produce viral proteins as well as cellular responses to viral infection that cause local inflammation. Prolonged inflammation from SARS-CoV-2 can lead to some of the severe outcomes experienced by infected patients. We aimed for the work by Evotec to provide us with information that could allow us to assess the potential path forward for the program. However, with the changes in the demand for COVID-19 therapeutic landscape, and potential capital required to advance the program, our management decided to currently pause additional development of this program. Tumor Targeting Technology TYME has developed a technology (“Tumor Targeting Technology”) by which the tyrosine isomer L metyrosine (L-α-methylparatyrosine) can be fused with a second therapeutic agent in a manner that creates a fusion compound that may allow targeted accumulation of the treatment by the cancer cells in a novel manner. The Company is assessing potential development paths forward for this technology. Discontinuing Programs Precision Promise Trial- SM-88 with MPS as 2 nd In October 2018 the Company partnered with PanCAN to study SM-88 in an adaptive randomized Phase II/III trial with registration intent known as Precision Promise SM On January 26, 2022, the Company announced the discontinuation of SM-88 with MPS in the Precision Promise trial in mPDAC upon learning from PanCAN, the trial sponsor, that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC. Based on the information provided by PanCAN, the OS for SM-88 with MPS in monotherapy was lower compared to standard of care chemotherapies with either Gemcitabine and Abraxane or modified FOLFIRINOX. As of June 30, 2022, remaining estimated costs to close out the trial have been expensed. TYME-88-PANC (Part 2) (third-line Metastatic Pancreatic Cancer) In fiscal year 2020, we launched our pivotal study for SM-88 in the third-line treatment of pancreatic cancer through an amendment to our ongoing TYME-88-Panc trial (Part 2), with the first patient dosed in the third quarter of the fiscal year. As described previously, the COVID-19 pandemic significantly impacted enrollment of this trial such that it appeared likely to complete enrollment in a similar timeline to the second-line Precision Promise pancreatic cancer trial. There was also a higher than expected dropout of patients randomized to the chemotherapy control arm, which could have potentially impacted the interpretative and regulatory utility of the data. Following the strategic review conducted in the first half of calendar year 2021, considering, in part, the timeline and regulatory utility for this trial compared to the parallel Precision Promise trial and concentration of investment in this specific cancer, management concluded that it would be best to focus on the second-line Precision Promise trial which offers treatment options to patients earlier in their disease and includes tumor biopsy and biomarker analyses that align with the Company’s overall strategic focus on identifying targeted therapies. In June 2021, the Company stopped enrollment and began the process of closing down the trial. It is expected to be completed in the third quarter of calendar year 2022, with remaining estimated costs to the Company of approximately $100,000. Merger Agreement with Syros Pharmaceuticals, Inc. On July 3, 2022, TYME entered into an Agreement and Plan of Merger (the “ Merger Agreement Merger Sub Merger continuing Effective Time each Tyme Common Stock Syros Common Stock Liquidity The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. In February 2021, the Company raised $100 million in gross proceeds through a registered direct offering of 40,000,000 shares of its common stock, at a purchase price of $2.50 per share. The Company incurred $6.2 million of related costs, which offset such proceeds. On January 7, 2020, the Company entered into an SPA with Eagle Pharmaceuticals, Inc. (“Eagle”), pursuant to which the Company raised $20.0 million through the issuance and sale to Eagle of 10,000,000 shares of common stock, at a price of $2.00 per share. On October 18, 2019, TYME entered into an Open Market Sale Agreement SM The proceeds of the aforementioned offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses. For the three months ended June 30, 2022, the Company had negative cash flow from operations of $4.8 million and net loss of $6.5 million, which included non-cash expenses of $0.5 million related to non-cash equity compensation, $0.4 million net amortization expense of premiums and discounts on marketable securities, and $0.8 million change in operating assets and liabilities. As of June 30, 2022, the Company had working capital of approximately $73.4 million. Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements . This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K, as amended, for the year ended March 31, 2022 filed with the SEC (the “2022 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiar y , Tyme Inc. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in ASC and ASU of the FASB. Significant Accounting Policies The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2022 included in the Company’s 2022 10-K. Cash and cash equivalents Cash and cash equivalents include demand deposit accounts, money market funds and municipal debt securities. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value. Marketable Securities All of the Company's marketable securities are debt securities and are classified as available-for-sale in accordance with the ASC Topic 320, “Investments - Debt and Equity Securities.” Available for sale securities are carried at fair value and reported in cash equivalents and marketable securities. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for a credit loss is recorded on our consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis. Fair Value of Financial Instruments The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. Cash equivalents, marketable securities and the derivative warrant liability are recorded at fair value. Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets (Level 1), and the lowest priority to unobservable inputs (Level 3). The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and their applicability to the Company’s financial assets, are described below. Level 1 : Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. Level 2 : Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. Level 3 : Pricing inputs are unobservable for the assets. Level 3 assets include private investments that are supported by little or no market activity. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis see Note 6 . Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise or certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the condensed consolidated statement of operations. As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features that cause the warrants to be treated as derivatives or requires the issuance of registered common shares upon exercise. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black-Scholes model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants (see Note 6). Risks and Uncertainties The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions The novel coronavirus (COVID-19) pandemic, and actions taken by governments and others to reduce its spread, has negatively impacted the global economy, financial markets, and the Company’s industry and has disrupted day-to-day life and business operations. Even as certain restrictions have been lifted, new processes implemented and vaccines have become more widely available and administered, spikes in infections (including the spread of new variants) continue to be experienced and certain jurisdictions continue to impose stay-at-home orders from time to time, as conditions evolve and fluctuate around the world. Additionally, supply chain disruptions, the effect of the Russia/Ukraine war, inflation and rising interest rates and the possibility of an economic recession further exacerbate challenging economic conditions. The extent to which the continuing COVID-19 pandemic and other macroeconomic headwinds impact our product candidates and business, including patients’ willingness to participate and remain in clinical trials, the timing of meeting enrollment expectations, the ability of our third-party partners to remain operational and our access to capital markets and financing sources, depends on numerous evolving factors that are highly uncertain, cannot be accurately predicted, and may be significant. Recent Accounting Pronouncements The Company has reviewed the Accounting Standards Updates recently issued by the FASB, and determined that they are not applicable to the Company.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 3. Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended June 30, 2022 2021 Basic and diluted net loss per common share calculation: Net loss $ (6,494,933 ) $ (5,929,163 ) Weighted average common shares outstanding — basic and diluted: 172,206,894 172,205,452 Net loss per share of common stock — basic and diluted $ (0.04 ) $ (0.03 ) The Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic net loss per share is computed by dividing net loss attributable to the Company by the weighted average number of shares of Company Common Stock outstanding for the period, and diluted EPS is computed by including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive. The following outstanding securities at June 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: June 30, 2022 2021 Stock options 17,253,306 15,554,575 Warrants 3,104,318 3,104,318 Total 20,357,624 18,658,893

Accounts Payable and Other Curr

Accounts Payable and Other Current Liabilities	3 Months Ended
	Jun. 30, 2022
Payables And Accruals [Abstract]
Accounts Payable and Other Current Liabilities	Note 4. Accounts Payable and Other Current Liabilities Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: June 30, 2022 March 31, 2022 Legal $ 577,176 $ 263,111 Consultant and professional services 1,451,807 300,051 Accounting and auditing 204,763 14,410 Research and development 2,285,779 2,776,594 Board of Directors and Scientific Advisory Board Compensation 117,139 418,389 Other 48,552 30,872 Total $ 4,685,216 $ 3,803,427

Severance Payable

Severance Payable	3 Months Ended
	Jun. 30, 2022
Severance Payable [Abstract]
Severance Payable	Note 5. Severance Payable The Company entered into a Release Agreement, dated March 24, 2022, pursuant to which the Chief Science Officer resigned and received severance that would be payable under his employment agreement in a lump sum payment of $2.1 million. Between April 12, 2021 and March 28, 2022, the Company also entered into separation and general release agreements with three other employees. The agreements provide separation benefits, which the Company recorded as severance expense. In April 2021, the Company entered into a Separation and General Release Agreement related to the separation of employment of its then-Chief Medical Officer as of March 31, 2021. The agreement provides for separation benefits which the Company recorded as severance expense for the year ended March 31, 2021. On March 15, 2019, the Company entered into a Release Agreement related to the separation of employment of its then-Chief Operating Officer. The agreement provides for salary continuance for five years, reimbursement of health benefits for three years and a modification to his outstanding stock options to extend the post-termination exercise period for his vested options from three months to five years. The Company recorded severance expense at its present value of $2.5 million (using a discount rate of 6%) for the year ended March 31, 2019, including $0.4 million relating to the stock option modification. The aggregate severance liability payable was $0.8 million and $3.0 million as of June 30, 2022 and March 31, 2022, respectively.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Fair Value Measurements The Company has segregated all financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below. Transfers are calculated on values as of the transfer date. There were no transfers between Levels 1, 2 and 3 during the three months ended June 30, 2022 and June 30, 2021. The Company’s financial instruments measured at fair value on a recurring basis as of June 30, 2022 and March 31, 2022 are as follows: Quoted prices in active markets Significant other observable inputs Significant unobservable inputs June 30, 2022 Total (Level 1) (Level 2) (Level 3) Financial assets Cash equivalents Money market funds $ 24,077 $ 24,077 $ — $ — Municipal debt securities 1,360,000 — 1,360,000 — Marketable Securities Short-term Commercial paper 6,426,250 — 6,426,250 — Corporate debt securities 29,769,174 — 29,769,174 — Municipal debt securities 34,494,699 — 34,494,699 — Long-term Municipal debt securities 1,113,824 — 1,113,824 — $ 73,188,024 $ 24,077 $ 73,163,947 $ — Financial liability Warrant liability $ 89,559 $ — $ — $ 89,559 Quoted prices in active markets Significant other observable inputs Significant unobservable inputs March 31, 2022 Total (Level 1) (Level 2) (Level 3) Financial assets Cash equivalents Money market funds $ 3,409,178 $ 3,409,178 $ — $ — Marketable Securities Short-term Corporate debt securities 26,195,025 — 26,195,025 — Municipal debt securities 34,416,936 — 34,416,936 — Long-term Corporate debt securities 6,293,015 — 6,293,015 — Municipal debt securities 2,787,656 — 2,787,656 — $ 73,101,810 $ 3,409,178 $ 69,692,632 $ — Financial liability Warrant liability $ 124,480 $ — $ — $ 124,480 Fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The fair value of cash equivalents held in money market funds is determined based on “Level 1” inputs. Marketable securities classified as Level 2 within the valuation hierarchy consist of corporate debt securities and municipal debt securities. We estimate the fair values of these marketable securities by taking into consideration valuations obtained from third-party pricing sources. These pricing sources utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include market pricing based on real-time trade data for the same or similar securities, issuer credit spreads, benchmark yields, and other observable inputs. The fair value measurement for the May 2020 Warrant issued in conjunction with the Exchange Agreements (see Note 8 for transaction details) is based on significant inputs not observable in the market and is classified as Level 3 liability as of June 30, 2022 and March 31, 2022. The fair value of the May 2020 Warrant was determined using a Black Scholes model and included significant unobservable inputs such as volatility. The model also incorporated several observable assumptions at each valuation date including: the price of the Company’s common stock on the date of valuation, the remaining contractual term of the warrant and the risk free interest rate over the term. The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of June 30, 2022 and March 31, 2022 using a Black Scholes model: June 30, 2022 March 31, 2022 Stock price $ 0.28 $ 0.35 Volatility 108 % 98 % Remaining term (years) 1.76 2.01 Expected dividend yield — — Risk-free rate 2.87 % 2.28 % The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: June 30, 2022 Beginning balance, March 31, 2022 $ 124,480 Change in fair value of May 2020 Warrant liability (34,921 ) Ending balance, June 30, 2022 $ 89,559

Available-for-Sale-Securities

Available-for-Sale-Securities	3 Months Ended
	Jun. 30, 2022
Investments Debt And Equity Securities [Abstract]
Available-for-Sale-Securities	Note 7. Available-for-Sale-Securities The following table summarizes available-for-sale securities recorded in cash and cash equivalents or marketable securities as of June 30, 2022 and March 31, 2022: June 30, 2022 March 31, 2022 Amortized cost Gross Unrealized Gains Gross Unrealized Loss Fair Value Amortized cost Gross Unrealized Gains Gross Unrealized Loss Fair Value Money market funds $ 24,077 $ — $ — $ 24,077 $ 3,409,178 $ — $ — $ 3,409,178 Commercial paper 6,426,250 — — 6,426,250 — — — — Corporate debt securities 30,125,510 35 (356,371 ) 29,769,174 32,831,174 — (343,134 ) 32,488,040 Municipal debt securities 37,145,949 2 (177,428 ) 36,968,523 37,405,722 — (201,130 ) 37,204,592 Total $ 73,721,786 $ 37 $ (533,799 ) $ 73,188,024 $ 73,646,074 $ — $ (544,264 ) $ 73,101,810 The following table summarizes the classification of available-for-sale securities: June 30, 2022 March 31, 2022 Cash and cash equivalents $ 1,384,077 $ 3,409,178 Marketable securities 71,803,947 69,692,632 Total $ 73,188,024 $ 73,101,810 The following table summarizes our portfolio of available-for-sale securities by contractual maturity: Less than 12 months 12 months or Longer Total Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Money market funds $ 24,077 $ — $ — $ - $ 24,077 $ — Commercial paper 6,426,250 — — — 6,426,250 — Corporate debt securities 29,769,174 (356,336 ) — — 29,769,174 (356,336 ) Municipal debt securities 35,854,699 (147,856 ) 1,113,824 (29,570 ) 36,968,523 (177,426 ) Total $ 72,074,200 $ (504,192 ) $ 1,113,824 $ (29,570 ) $ 73,188,024 $ (533,762 )

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders' Equity	Note 8. Stockholders’ Equity Common Stock Voting In connection with the Release Agreement, dated March 24, 2022, the Company and Mr. Hoffman also entered into a Voting Agreement, pursuant to which Mr. Hoffman agreed to vote all shares of TYME common stock beneficially owned by him in accordance with the Board’s recommendation with respect to any matter presented to the stockholders for a period of one year. The Company and Michael Demurjian entered into a Voting Agreement, dated April 18, 2022, pursuant to which Mr. Demurjian agreed to vote all shares of TYME common stock beneficially owned by him in accordance with the board of directors of the Company’s recommendation with respect to any matter presented to the Company’s stockholders for a period of two years from the date of the agreement. Exchange Agreements On May 20, 2020, the Company entered into exchange agreements with holders (the “Holders”) of the warrants issued in April 2019 (the “April 2019 Warrants”). The April 2019 Warrants were offered and issued pursuant to the Company’s previous shelf registration statement on Form S-3 (File No. 333-211489). Pursuant to exchange agreements (the “Share Exchange Agreements”) with Holders of the April 2019 Warrants to purchase 5,833,333 shares of Common Stock in the aggregate, the Company issued an aggregate of 2,406,250 shares of common stock (the “Exchange Shares”) in exchange for such April 2019 Warrants. The Company also entered into an exchange agreement (the “Warrant Exchange Agreement”) with another Holder of April 2019 Warrants to purchase 2,166,667 shares of Common Stock in the aggregate. Pursuant to the Warrant Exchange Agreement, the Company issued such Holder a new warrant (the “May 2020 Warrant”) to purchase the same number of shares of Common Stock. The May 2020 Warrant has the same expiration date, April 2, 2024, as the April 2019 Warrants, but has an exercise price of $1.80 and does not include certain price protection, anti-dilution provisions or other restrictions on Company action from the April 2019 Warrants. The exercise price of the May 2020 Warrant is subject to adjustment upon the occurrence of specific events, including stock dividends, stock splits, combinations and reclassifications of the Company’s Common Stock. The Company determined that the May 2020 Warrant should be recorded as a derivative liability on the condensed consolidated balance sheet due to the May 2020 Warrant’s contractual provisions requiring issuance of registered common shares upon exercise. See Note 6 for the change in fair value disclosures. The following summarizes the common stock warrant activity for the three months ended June 30, 2022: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2022 3,104,318 $ 2.77 Granted — — Exchanged — — Outstanding at June 30, 2022 3,104,318 $ 2.77 At each of June 30, 2022 and March 31, 2022, 3,074,551, of common stock purchase warrants relating to SPAs were outstanding and exercisable. Warrants The Company has warrants to purchase its common stock outstanding as of June 30, 2022, as follows: Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 May 2020 Liability 2,166,667 $ 1.80 April 2024 At-the-Market Financing Facility On October 18, 2019, the Company entered into the Sale Agreement with Jefferies, which was amended on August 12, 2020, pursuant to which the Company may, from time to time, sell shares of common stock, having an aggregate offering price of up to $30.0 million through Jefferies, as the Company’s sales agent. As indicated in the amendment, the shares will be offered and sold by the Company pursuant to its currently effective Registration Statement on Form S-3, as amended (Reg. No. 333-245033). Any sales of common stock pursuant to the Sales Agreement will be made by methods deemed to be an “at-the-market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies will use commercially reasonable efforts to sell the shares from time to time, based on the instructions of the Company. The Company will pay Jefferies a commission rate of three percent (3%) of the gross proceeds from the sales of shares of Common Stock sold pursuant to the Sale Agreement. Under the Sale Agreement, the Company is not required to use the full available amount authorized and it may, by giving notice as specified in the Sale Agreement, terminate the Sale Agreement at any time The Company did not sell any shares through the Jefferies ATM during the three months ended June 30, 2022 and June 30, 2021. At June 30, 2022, there remained approximately $22.2 million of availability to sell shares through the Jefferies ATM subject to the terms of the Sale Agreement. Securities Purchase Agreement On January 7, 2020, the Company and Eagle entered into the Eagle SPA, pursuant to which the Company issued and sold to Eagle 10,000,000 shares of common stock, at a price of $2.00 per share. The Eagle SPA provides that Eagle will, subject to certain conditions, make an additional payment of $20 million upon the occurrence of a milestone event, which is defined as the earlier of ( i) achievement of the On July 3, 2022, Eagle entered into a Support Agreement with Syros and TYME, in which it agreed, to, among other things, vote all of its shares in TYME that it owns as of the record date for the applicable stockholder meeting (i) in favor of the adoption of the proposals required for the Merger, (ii) against any competing acquisition proposal, and (iii) against any proposal, action or agreement that would reasonably be expected to impede, interfere with, delay or postpone, prevent or otherwise impair the Merger or the other transactions contemplated by the Merger Agreement. Registered Direct Offering On 2020

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Jun. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Contract Service Providers In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. At June 30, 2022, the Company’s obligations to contract service providers were $0.1 million in the aggregate. On April 1, 2020, the Company amended the Clinical Research Funding and Drug Supply Agreement dated October 9, 2018, with PanCAN, to enroll individuals diagnosed with pancreatic cancer in a platform style clinical research study. Stage 1 of the study was initiated in the fourth quarter of fiscal year 2020. On January 26, 2022, the Company announced the discontinuation of SM-88 with MPS in the Precision Promise trial in mPDAC upon learning from PanCAN, the trial sponsor, that it terminated the arm due to futility compared to the control of standard of care chemotherapy in second-line mPDAC. As of June 30, 2022, remaining estimated costs to close out the trial have been expensed. Purchase Commitments The Company has entered into contracts with manufacturers to supply SM-88 and certain related conditioning agents, in order to achieve favorable pricing on supplied products. These contracts have non-cancellable elements related to the scheduled deliveries of these products in future periods. Payments are made by us to the manufacturer when the products are delivered and of acceptable quality. The outstanding future contract obligations structured to match clinical supply needs for the Company’s ongoing trials and registration activity are approximately $0.6 million and $2.4 million, respectively, at June 30, 2022. Legal Proceedings The Company is not currently a party to any material legal proceedings and is not aware of any pending or threatened legal proceeding against it that it believes could have a material adverse effect on the Company, its business, operating results or financial condition. From time to time, the Company may be involved in litigation, claims or other contingencies arising in the ordinary course of business. The Company would accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company would not record a liability, but instead would disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such estimate can be made. Legal fees are expensed as incurred.

Leases

Leases	3 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Leases	Note 10. Leases The Company has a lease for office space in New Jersey, which expires in February 2023. Total Company rent expense, including short term rentals, was approximately $13,000 and $14,000 for the three months ended June 30, 2022 and June 30, 2021, respectively. Operating lease ROU assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease ROU assets and liabilities. The Company uses its incremental borrowing rate of 11.0% to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable. As of June 30, 2022, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease ROU assets and lease liabilities were as follows: June 30, 2022 Fiscal year 2023 $ 27,468 Total remaining lease payments 27,468 Less: present value adjustment (980 ) Total operating lease liabilities 26,488 Less: current portion (26,488 ) Operating lease liabilities, net of current portion $ —

Related Party Transactions

Related Party Transactions	3 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Legal Faegre Drinker Biddle & Reath (“Faegre Drinker”), formerly Drinker Biddle & Reath LLP (“DBR”), has provided legal services to the Company. The Company’s Chief Legal Officer and Corporate Secretary held the consulting role “Senior Counsel” with Faegre Drinker until December 31, 2021. The Company disclosed legal fees incurred and accounts payable and accrued expenses associated with Faegre Drinker through the fiscal year end of which the related party transaction with the law firm was terminated. Faegre Drinker continues to provide services to the Company, but is no longer a related party. Legal fees incurred associated with the related party transaction with Faegre Drinker were approximately $115,000 for the three months ended June 30, 2021. At March 31, 2022, the Company had approximately $153,000 in related party transaction costs.

Equity Incentive Plan

Equity Incentive Plan	3 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	Note 12. Equity Incentive Plan Stock Options As of June 30, 2022, there was approximately $4.9 million of total unrecognized compensation expense related to non-vested stock options. The cost is expected to be recognized over the remaining weighted average service period of 2.8 years. As of June 30, 2022, there were 7,885,273 shares available for grant under the Company’s 2015 Equity Incentive Plan and 2016 Director Plan. Stock based compensation expense was recognized as follows: Three Months Ended June 30, 2022 2021 General and administrative $ 451,000 $ 471,000 Research and development 89,000 173,000 Total $ 540,000 $ 644,000 The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. For employees and non-employees, the compensation expense is amortized on a straight-line basis over the requisite service period, which approximates the vesting period. The Company accounts for forfeitures as they occur, rather than estimating forfeitures as of an award’s grant date. The expected volatility of options granted has been determined using the method described under ASC 718 using the expected volatility of similar companies. The expected term of options granted to employees, non-employees and consultants in the current fiscal period has been based on the term by using the simplified method as allowed under SAB No. 110 and ASU 2018-7. The weighted average assumptions used to determine such values are presented in the following table: June 30, 2022 June 30, 2021 Risk free interest rate 2.83% - 2.92% 0.28% - 1.01% Expected volatility 115.36% - 115.39% 97.11% - 105.37% Expected term (in years) 6.1 2.7 - 6.1 Dividend yield 0 % 0 % The following is a summary of the status of the Company’s stock options for the three months ended June 30, 2022: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2022 14,504,271 $ 2.36 Granted 3,641,300 $ 0.32 Cancelled/Forfeited (892,265 ) $ 5.47 Exercised — $ — Outstanding at June 30, 2022 17,253,306 $ 1.77 Options exercisable at June 30, 2022 9,387,474 $ 2.55 Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at June 30, 2022 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at June 30, 2022 Weighted Average Exercise Price Aggregate Intrinsic Value $0.29 - $8.75 17,253,306 $ 1.77 7.5 $ - 9,387,474 $ 2.55 $ - The intrinsic value calculated as the excess of the market value as of June 30, 2022 over the exercise price of the options is $0. The market value per share as of June 30, 2022 was $0.28 as reported by the NASDAQ Capital Market.

Income Taxes

Income Taxes	3 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 13. Income Taxes A valuation allowance is recorded if it is more likely than not that a deferred tax asset will not be realized. The Company weighed available positive and negative evidence and concluded that a full valuation allowance should continue to be maintained on its net deferred tax assets. The Company is required to evaluate uncertain tax positions taken or expected to be taken in the course of preparing the Company’s condensed consolidated financial statements to determine whether the tax positions are more likely than not of being sustained by the applicable tax authority. As of June 30, 2022, the Company’s uncertain tax positions remain unchanged. Due to the full valuation allowance, none of the gross unrecognized tax benefits, if recognized, would affect the effective tax rate at June 30, 2022. The Company had no income tax related penalties or interest for periods presented in these condensed consolidated financial statements related to uncertain tax positions due to available net operating loss carryforwards, which would be recorded as tax expense should the Company accrue for such items.

Subsequent Events

Subsequent Events	3 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events Merger Agreement with Syros Pharmaceuticals, Inc. On July 3, 2022, TYME entered into the Merger Agreement with Syros and Merger Sub. Upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into TYME, with TYME continuing each

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements and related notes should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K, as amended, for the year ended March 31, 2022 filed with the SEC (the “2022 10-K”). The condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are necessary to present fairly the results for the interim periods. All such adjustments are of a normal and recurring nature. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. The Company’s condensed consolidated financial statements include the accounts of Tyme Technologies, Inc. and its subsidiar y , Tyme Inc. All intercompany transactions and balances have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in ASC and ASU of the FASB.
Principles of Consolidation	The Company’s significant accounting policies are disclosed in the audited financial statements for the year ended March 31, 2022 included in the Company’s 2022 10-K.
Cash and Cash Equivalents	Cash and cash equivalents Cash and cash equivalents include demand deposit accounts, money market funds and municipal debt securities. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.
Marketable Securities	Marketable Securities All of the Company's marketable securities are debt securities and are classified as available-for-sale in accordance with the ASC Topic 320, “Investments - Debt and Equity Securities.” Available for sale securities are carried at fair value and reported in cash equivalents and marketable securities. For individual debt securities classified as available-for-sale securities where there has been a decline in fair value below amortized cost, the Company determines whether the decline resulted from a credit loss or other factors. In making this assessment, the Company considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for a credit loss is recorded on our consolidated balance sheet, limited by the amount that the fair value is less than the amortized cost basis.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts reported in the Company’s condensed consolidated financial statements for cash, accounts payable, and other current liabilities approximate their respective fair values because of the short-term nature of these accounts. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. Cash equivalents, marketable securities and the derivative warrant liability are recorded at fair value. Fair value is defined as the price that would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets (Level 1), and the lowest priority to unobservable inputs (Level 3). The Company’s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the fair value hierarchy, and their applicability to the Company’s financial assets, are described below. Level 1 : Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. Level 2 : Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. Level 3 : Pricing inputs are unobservable for the assets. Level 3 assets include private investments that are supported by little or no market activity. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis see Note 6 .
Derivative Warrant Liability	Derivative Warrant Liability Certain freestanding common stock warrants that are related to the issuance of common stock are classified as liabilities and recorded at fair value due to characteristics that require liability accounting, primarily the obligation to issue registered shares of common stock upon notification of exercise or certain price protection provisions. Warrants of this type are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of other income (expense) in the condensed consolidated statement of operations. As noted in Note 8, Stockholders’ Equity, the Company classifies a warrant to purchase shares of its common stock as a liability on its condensed consolidated balance sheet if the warrant is a free-standing financial instrument that contains certain price protection features that cause the warrants to be treated as derivatives or requires the issuance of registered common shares upon exercise. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model or the Black-Scholes model, and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrant are recognized as a component of other income (expense) in the consolidated statement of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrant. The Company utilizes Level 3 fair value criteria to measure the fair value of the warrants (see Note 6).
Risks and Uncertainties	Risks and Uncertainties The Company is subject to those risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Current Economic Conditions The novel coronavirus (COVID-19) pandemic, and actions taken by governments and others to reduce its spread, has negatively impacted the global economy, financial markets, and the Company’s industry and has disrupted day-to-day life and business operations. Even as certain restrictions have been lifted, new processes implemented and vaccines have become more widely available and administered, spikes in infections (including the spread of new variants) continue to be experienced and certain jurisdictions continue to impose stay-at-home orders from time to time, as conditions evolve and fluctuate around the world. Additionally, supply chain disruptions, the effect of the Russia/Ukraine war, inflation and rising interest rates and the possibility of an economic recession further exacerbate challenging economic conditions. The extent to which the continuing COVID-19 pandemic and other macroeconomic headwinds impact our product candidates and business, including patients’ willingness to participate and remain in clinical trials, the timing of meeting enrollment expectations, the ability of our third-party partners to remain operational and our access to capital markets and financing sources, depends on numerous evolving factors that are highly uncertain, cannot be accurately predicted, and may be significant.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company has reviewed the Accounting Standards Updates recently issued by the FASB, and determined that they are not applicable to the Company.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Three Months Ended June 30, 2022 2021 Basic and diluted net loss per common share calculation: Net loss $ (6,494,933 ) $ (5,929,163 ) Weighted average common shares outstanding — basic and diluted: 172,206,894 172,205,452 Net loss per share of common stock — basic and diluted $ (0.04 ) $ (0.03 )
Schedule of Anti-dilutive Shares Outstanding	The following outstanding securities at June 30, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding, as they are anti-dilutive: June 30, 2022 2021 Stock options 17,253,306 15,554,575 Warrants 3,104,318 3,104,318 Total 20,357,624 18,658,893

Accounts Payable and Other Cu_2

Accounts Payable and Other Current Liabilities (Tables)	3 Months Ended
	Jun. 30, 2022
Payables And Accruals [Abstract]
Schedule of Accounts Payable and Other Current Liabilities	Accounts payable (including accounts payable to a related party – see Note 11) and other current liabilities consisted of the following: June 30, 2022 March 31, 2022 Legal $ 577,176 $ 263,111 Consultant and professional services 1,451,807 300,051 Accounting and auditing 204,763 14,410 Research and development 2,285,779 2,776,594 Board of Directors and Scientific Advisory Board Compensation 117,139 418,389 Other 48,552 30,872 Total $ 4,685,216 $ 3,803,427

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Instruments Measured at Fair Value on Recurring Basis	The Company’s financial instruments measured at fair value on a recurring basis as of June 30, 2022 and March 31, 2022 are as follows: Quoted prices in active markets Significant other observable inputs Significant unobservable inputs June 30, 2022 Total (Level 1) (Level 2) (Level 3) Financial assets Cash equivalents Money market funds $ 24,077 $ 24,077 $ — $ — Municipal debt securities 1,360,000 — 1,360,000 — Marketable Securities Short-term Commercial paper 6,426,250 — 6,426,250 — Corporate debt securities 29,769,174 — 29,769,174 — Municipal debt securities 34,494,699 — 34,494,699 — Long-term Municipal debt securities 1,113,824 — 1,113,824 — $ 73,188,024 $ 24,077 $ 73,163,947 $ — Financial liability Warrant liability $ 89,559 $ — $ — $ 89,559 Quoted prices in active markets Significant other observable inputs Significant unobservable inputs March 31, 2022 Total (Level 1) (Level 2) (Level 3) Financial assets Cash equivalents Money market funds $ 3,409,178 $ 3,409,178 $ — $ — Marketable Securities Short-term Corporate debt securities 26,195,025 — 26,195,025 — Municipal debt securities 34,416,936 — 34,416,936 — Long-term Corporate debt securities 6,293,015 — 6,293,015 — Municipal debt securities 2,787,656 — 2,787,656 — $ 73,101,810 $ 3,409,178 $ 69,692,632 $ — Financial liability Warrant liability $ 124,480 $ — $ — $ 124,480
Schedule of Key Inputs and Assumptions to Estimate the Fair Value of Warrant	The following table details key inputs and assumptions used to estimate the fair value of the May 2020 Warrant as of June 30, 2022 and March 31, 2022 using a Black Scholes model: June 30, 2022 March 31, 2022 Stock price $ 0.28 $ 0.35 Volatility 108 % 98 % Remaining term (years) 1.76 2.01 Expected dividend yield — — Risk-free rate 2.87 % 2.28 %
Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs	The following table summarizes activity for liabilities measured at fair value using Level 3 significant unobservable inputs: June 30, 2022 Beginning balance, March 31, 2022 $ 124,480 Change in fair value of May 2020 Warrant liability (34,921 ) Ending balance, June 30, 2022 $ 89,559

Available-for-Sale-Securities (

Available-for-Sale-Securities (Tables)	3 Months Ended
	Jun. 30, 2022
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-Sale Securities Recorded In Cash and Cash Equivalents or Marketable Securities	The following table summarizes available-for-sale securities recorded in cash and cash equivalents or marketable securities as of June 30, 2022 and March 31, 2022: June 30, 2022 March 31, 2022 Amortized cost Gross Unrealized Gains Gross Unrealized Loss Fair Value Amortized cost Gross Unrealized Gains Gross Unrealized Loss Fair Value Money market funds $ 24,077 $ — $ — $ 24,077 $ 3,409,178 $ — $ — $ 3,409,178 Commercial paper 6,426,250 — — 6,426,250 — — — — Corporate debt securities 30,125,510 35 (356,371 ) 29,769,174 32,831,174 — (343,134 ) 32,488,040 Municipal debt securities 37,145,949 2 (177,428 ) 36,968,523 37,405,722 — (201,130 ) 37,204,592 Total $ 73,721,786 $ 37 $ (533,799 ) $ 73,188,024 $ 73,646,074 $ — $ (544,264 ) $ 73,101,810
Summary of Classification of Available-for-Sale Securities	The following table summarizes the classification of available-for-sale securities: June 30, 2022 March 31, 2022 Cash and cash equivalents $ 1,384,077 $ 3,409,178 Marketable securities 71,803,947 69,692,632 Total $ 73,188,024 $ 73,101,810
Summary of Available-for-Sale Securities By Contractual Maturity	The following table summarizes our portfolio of available-for-sale securities by contractual maturity: Less than 12 months 12 months or Longer Total Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Fair Value Net Unrealized Losses Money market funds $ 24,077 $ — $ — $ - $ 24,077 $ — Commercial paper 6,426,250 — — — 6,426,250 — Corporate debt securities 29,769,174 (356,336 ) — — 29,769,174 (356,336 ) Municipal debt securities 35,854,699 (147,856 ) 1,113,824 (29,570 ) 36,968,523 (177,426 ) Total $ 72,074,200 $ (504,192 ) $ 1,113,824 $ (29,570 ) $ 73,188,024 $ (533,762 )

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Common Stock Warrant Activity	The following summarizes the common stock warrant activity for the three months ended June 30, 2022: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2022 3,104,318 $ 2.77 Granted — — Exchanged — — Outstanding at June 30, 2022 3,104,318 $ 2.77
Schedule of Warrants to Purchase Common Stock Outstanding	The Company has warrants to purchase its common stock outstanding as of June 30, 2022, as follows: Issued Classification Warrants Outstanding Exercise Price Expiration December 2015 Equity 446,500 $ 5.00 December 2025 February 2016 Equity 461,384 $ 5.00 February 2026 July 2016 Equity 29,767 $ 5.00 June 2026 May 2020 Liability 2,166,667 $ 1.80 April 2024

Leases (Tables)

Leases (Tables)	3 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements	As of June 30, 2022, the future minimum lease payments under non-cancellable operating lease agreements for which the Company has recognized operating lease ROU assets and lease liabilities were as follows: June 30, 2022 Fiscal year 2023 $ 27,468 Total remaining lease payments 27,468 Less: present value adjustment (980 ) Total operating lease liabilities 26,488 Less: current portion (26,488 ) Operating lease liabilities, net of current portion $ —

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	3 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock based compensation expense	Stock based compensation expense was recognized as follows: Three Months Ended June 30, 2022 2021 General and administrative $ 451,000 $ 471,000 Research and development 89,000 173,000 Total $ 540,000 $ 644,000
Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted	The weighted average assumptions used to determine such values are presented in the following table: June 30, 2022 June 30, 2021 Risk free interest rate 2.83% - 2.92% 0.28% - 1.01% Expected volatility 115.36% - 115.39% 97.11% - 105.37% Expected term (in years) 6.1 2.7 - 6.1 Dividend yield 0 % 0 %
Schedule of Stock Options	The following is a summary of the status of the Company’s stock options for the three months ended June 30, 2022: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2022 14,504,271 $ 2.36 Granted 3,641,300 $ 0.32 Cancelled/Forfeited (892,265 ) $ 5.47 Exercised — $ — Outstanding at June 30, 2022 17,253,306 $ 1.77 Options exercisable at June 30, 2022 9,387,474 $ 2.55
Schedule of Stock Option by Exercise Price Range	Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at June 30, 2022 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at June 30, 2022 Weighted Average Exercise Price Aggregate Intrinsic Value $0.29 - $8.75 17,253,306 $ 1.77 7.5 $ - 9,387,474 $ 2.55 $ -

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($)			3 Months Ended
	Feb. 08, 2021	Jan. 07, 2020	Jun. 30, 2022	Jun. 30, 2021	Jul. 03, 2022	Mar. 31, 2022	Oct. 18, 2019
Nature Of Business [Line Items]
Remaining estimated closure costs of trial			$ 100,000
Common stock, par value (in dollars per share)			$ 0.0001			$ 0.0001
Net cash used in operating activities			$ (4,781,433)	$ (5,809,337)
Net loss			(6,494,933)	(5,929,163)
Non-cash equity compensation			540,472	643,665
Net amortization of premiums and discounts on marketable securities			389,117	$ 227,303
Change in operating assets and liabilities			800,000
Working capital			$ 73,400,000
Registered Direct Offering [Member]
Nature Of Business [Line Items]
Proceeds from issuance of common stock	$ 100,000,000
Related cost offset the proceeds	$ 6,200,000
Registered Direct Offering [Member] | Common Stock [Member]
Nature Of Business [Line Items]
Common stock, par value (in dollars per share)	$ 0.0001
Number of shares issued upon new issue	40,000,000
Share price (in dollars per share)	$ 2.50
Subsequent Event [Member]
Nature Of Business [Line Items]
Common stock, par value (in dollars per share)					$ 0.0001
Syros Pharmaceuticals Inc [Member] | Subsequent Event [Member]
Nature Of Business [Line Items]
Common stock, par value (in dollars per share)					$ 0.001
Eagle Pharmaceuticals, Inc [Member] | Securities Purchase Agreement [Member]
Nature Of Business [Line Items]
Share price (in dollars per share)		$ 2
Eagle Pharmaceuticals, Inc [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]
Nature Of Business [Line Items]
Number of shares issued upon new issue		10,000,000
Share price (in dollars per share)		$ 2
Proceeds from issuance of common stock		$ 20,000,000
Jefferies [Member] | Sale Agreement [Member]
Nature Of Business [Line Items]
Number of shares issued upon new issue			0	0
Available for offering			$ 22,200,000
Jefferies [Member] | Sale Agreement [Member] | Maximum [Member]
Nature Of Business [Line Items]
Aggregate offering							$ 30,000,000

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Basic and diluted net loss per common share calculation:
Net loss	$ (6,494,933)	$ (5,929,163)
Weighted average common shares outstanding — basic	172,206,894	172,205,452
Weighted average common shares outstanding — diluted	172,206,894	172,205,452
Net loss per share of common stock — basic	$ (0.04)	$ (0.03)
Net loss per share of common stock — diluted	$ (0.04)	$ (0.03)

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Anti-dilutive Shares Outstanding (Detail) - shares	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	20,357,624	18,658,893
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	17,253,306	15,554,575
Warrant [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	3,104,318	3,104,318

Accounts Payable and Other Cu_3

Accounts Payable and Other Current Liabilities - Schedule of Accounts Payable and Other Current Liabilities (Detail) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Payables And Accruals [Abstract]
Legal	$ 577,176	$ 263,111
Consultant and professional services	1,451,807	300,051
Accounting and auditing	204,763	14,410
Research and development	2,285,779	2,776,594
Board of Directors and Scientific Advisory Board Compensation	117,139	418,389
Other	48,552	30,872
Total	$ 4,685,216	$ 3,803,427

Severance Payable - Additional

Severance Payable - Additional Information (Detail) $ in Millions		12 Months Ended
	Mar. 15, 2019	Mar. 31, 2022 USD ($) Employee	Mar. 31, 2019 USD ($)	Jun. 30, 2022 USD ($)
Severance Payable [Line Items]
Severance expense			$ 2.5
Number of employees entered into separation and general agreement | Employee		3
Salary continuance term	5 years
Reimbursement of health benefits term	3 years
Discount rate			6%
Stock option modification expense			$ 0.4
Severance liability		$ 3		$ 0.8
Chief Science Officer [Member]
Severance Payable [Line Items]
Severance expense		$ 2.1
Release Agreement, March 15, 2019 [Member] | Minimum [Member]
Severance Payable [Line Items]
Post-termination exercise period	3 months
Release Agreement, March 15, 2019 [Member] | Maximum [Member]
Severance Payable [Line Items]
Post-termination exercise period	5 years

Fair Value of Financial Instrum

Fair Value of Financial Instruments - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	$ 1,384,077	$ 3,409,178
Marketable securities	70,690,123	60,611,961
Marketable securities	1,113,824	9,080,671
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets	73,188,024	73,101,810
Warrant liability	89,559	124,480
Fair Value, Measurements, Recurring [Member] | Corporate Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	29,769,174	26,195,025
Marketable securities		6,293,015
Fair Value, Measurements, Recurring [Member] | Municipal Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	1,360,000
Marketable securities	34,494,699	34,416,936
Marketable securities	1,113,824	2,787,656
Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets	24,077	3,409,178
Fair Value, Measurements, Recurring [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets	73,163,947	69,692,632
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Corporate Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	29,769,174	26,195,025
Marketable securities		6,293,015
Fair Value, Measurements, Recurring [Member] | Level 2 [Member] | Municipal Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	1,360,000
Marketable securities	34,494,699	34,416,936
Marketable securities	1,113,824	2,787,656
Fair Value, Measurements, Recurring [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrant liability	89,559	124,480
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	24,077	3,409,178
Money Market Funds [Member] | Fair Value, Measurements, Recurring [Member] | Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Cash equivalents	24,077	$ 3,409,178
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	6,426,250
Commercial Paper [Member] | Fair Value, Measurements, Recurring [Member] | Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Marketable securities	$ 6,426,250

Fair Value of Financial Instr_2

Fair Value of Financial Instruments - Schedule of Key Inputs and Assumption to Estimate the Fair Value of Warrant (Detail) - Warrant [Member] - Class Of Warrant Or Right Issued on May 2020 [Member]	Jun. 30, 2022 $ / shares	Mar. 31, 2022 $ / shares
Class Of Warrant Or Right [Line Items]
Stock price	$ 0.28	$ 0.35
Volatility [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	1.08	0.98
Remaining Term [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	1 year 9 months 3 days	2 years 3 days
Risk-free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Fair value assumptions	0.0287	0.0228

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Activity for Liabilities Measured at Fair Value using Level 3 Significant Unobservable Inputs (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Change in fair value of warrant liability	$ (34,921)	$ (725,143)
Level 3 [Member] | Class Of Warrant Or Right Issued on May 2020 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Beginning balance, March 31, 2022	124,480
Change in fair value of warrant liability	(34,921)
Ending balance, June 30, 2022	$ 89,559

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-Sale Securities Recorded In Cash and Cash Equivalents or Marketable Securities (Detail) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	$ 73,721,786	$ 73,646,074
Gross Unrealized Gains	37
Gross Unrealized Loss	(533,799)	(544,264)
Fair Value	73,188,024	73,101,810
Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	24,077	3,409,178
Fair Value	24,077	3,409,178
Corporate Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	30,125,510	32,831,174
Gross Unrealized Gains	35
Gross Unrealized Loss	(356,371)	(343,134)
Fair Value	29,769,174	32,488,040
Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	6,426,250
Fair Value	6,426,250
Municipal Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized cost	37,145,949	37,405,722
Gross Unrealized Gains	2
Gross Unrealized Loss	(177,428)	(201,130)
Fair Value	$ 36,968,523	$ 37,204,592

Available-for-Sale Securities_2

Available-for-Sale Securities - Summary of Classification of Available-for-Sale Securities (Detail) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Investments Debt And Equity Securities [Abstract]
Cash equivalents	$ 1,384,077	$ 3,409,178
Marketable securities	71,803,947	69,692,632
Total	$ 73,188,024	$ 73,101,810

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Available-for-Sale Securities By Contractual Maturity (Detail) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	$ 72,074,200
Less than 12 months, Net Unrealized Losses	(504,192)
12 months or Longer, Fair Value	1,113,824
12 months or Longer, Net Unrealized Losses	(29,570)
Total	73,188,024	$ 73,101,810
Total, Net Unrealized Losses	(533,762)
Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	24,077
Total	24,077	3,409,178
Corporate Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	29,769,174
Less than 12 months, Net Unrealized Losses	(356,336)
Total	29,769,174	32,488,040
Total, Net Unrealized Losses	(356,336)
Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	6,426,250
Total	6,426,250
Municipal Debt Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Less than 12 months, Fair Value	35,854,699
Less than 12 months, Net Unrealized Losses	(147,856)
12 months or Longer, Fair Value	1,113,824
12 months or Longer, Net Unrealized Losses	(29,570)
Total	36,968,523	$ 37,204,592
Total, Net Unrealized Losses	$ (177,426)

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)					3 Months Ended
	Feb. 08, 2021	May 20, 2020	Jan. 07, 2020	Oct. 18, 2019	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022
Stockholders Equity [Line Items]
Common stock, par value (in dollars per share)					$ 0.0001		$ 0.0001
Sale Agreement [Member] | Jefferies [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue					0	0
Payment of commission rate from gross proceeds				3%
Available for offering					$ 22,200,000
Sale Agreement [Member] | Jefferies [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Aggregate offering				$ 30,000,000
Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]
Stockholders Equity [Line Items]
Common stock price per share			$ 2
Milestone payments upon occurrence of milestone event payable			$ 20,000,000
Milestone payments upon occurrence of milestone event payable in cash			10,000,000
Milestone payments upon occurrence of milestone event payable in shares			$ 10,000,000
Milestone payments upon occurrence of milestone event payable in shares, Percentage of premium over share price			15%
Restricted period for Sale of shares description					shares will be restricted from sale until the earlier of three months following the milestone event or the three-year anniversary of the agreement
Registered Direct Offering [Member]
Stockholders Equity [Line Items]
Proceeds from issuance of common stock	$ 100,000,000
Related cost offset the proceeds	$ 6,200,000
Common Stock [Member] | Securities Purchase Agreement [Member] | Eagle Pharmaceuticals, Inc [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue			10,000,000
Proceeds from issuance of common stock			$ 20,000,000
Common stock price per share			$ 2
Common Stock [Member] | Registered Direct Offering [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue	40,000,000
Common stock price per share	$ 2.50
Common stock, par value (in dollars per share)	$ 0.0001
Share Exchange Agreements [Member]
Stockholders Equity [Line Items]
Number of shares that can be purchased with warrants		5,833,333
Share Exchange Agreements [Member] | Common Stock [Member]
Stockholders Equity [Line Items]
Number of shares issued upon new issue		2,406,250
Warrant Exchange Agreements [Member]
Stockholders Equity [Line Items]
Number of shares that can be purchased with warrants		2,166,667
Warrants expiration date		Apr. 02, 2024
Exercise price		$ 1.80
Securities Purchase Agreement [Member] | Warrant [Member]
Stockholders Equity [Line Items]
Common stock purchase warrants outstanding and exercisable					3,074,551		3,074,551

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Detail)	3 Months Ended
	Jun. 30, 2022 $ / shares shares
Equity [Abstract]
Warrant Shares of Common Stock, Outstanding at beginning | shares	3,104,318
Warrant Shares of Common Stock, Granted | shares	0
Warrant Shares of Common Stock, Exchanged | shares	0
Warrant Shares of Common Stock, Outstanding at ending | shares	3,104,318
Weighted Average Exercise Price, Outstanding at beginning | $ / shares	$ 2.77
Weighted Average Exercise Price, Granted | $ / shares	0
Weighted Average Exercise Price, Exchanged | $ / shares	0
Weighted Average Exercise Price, Outstanding at ending | $ / shares	$ 2.77

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Detail) - $ / shares	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	3,104,318	3,104,318
Class Of Warrant Or Right Issued on December 2015 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2015-12
Classification	Equity
Warrants Outstanding	446,500
Exercise Price	$ 5
Expiration	2025-12
Class Of Warrant Or Right Issued on February 2016 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2016-02
Classification	Equity
Warrants Outstanding	461,384
Exercise Price	$ 5
Expiration	2026-02
Class Of Warrant Or Right Issued on July 2016 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2016-07
Classification	Equity
Warrants Outstanding	29,767
Exercise Price	$ 5
Expiration	2026-06
Class Of Warrant Or Right Issued on May 2020 [Member] | Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Issued	2020-05
Classification	Liability
Warrants Outstanding	2,166,667
Exercise Price	$ 1.80
Expiration	2024-04

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail) $ in Millions	Jun. 30, 2022 USD ($)
Commitment And Contingencies [Line Items]
Contractual obligation	$ 0.1
Ongoing Clinical Trials [Member]
Commitment And Contingencies [Line Items]
Contractual obligation	0.6
Clinical Registration Activity [Member]
Commitment And Contingencies [Line Items]
Contractual obligation	$ 2.4

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Lessee Lease Description [Line Items]
Rent expense	$ 13,000	$ 14,000
Incremental borrowing rate to calculate present value of lease payments	11%
New Jersey [Member] | Office Space [Member]
Lessee Lease Description [Line Items]
Operating lease, expiration term	2023-02

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments under Non-Cancellable Operating Lease Agreements (Detail) - USD ($)	Jun. 30, 2022	Mar. 31, 2022
Operating Lease Liabilities Payments Due [Abstract]
Fiscal year 2023	$ 27,468
Total remaining lease payments	27,468
Less: present value adjustment	(980)
Total operating lease liabilities	26,488
Less: current portion	$ (26,488)	$ (37,332)

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Faegre Drinker Biddle & Reath ("Faegre Drinker") [Member] - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2021	Mar. 31, 2022
Related Party Transaction [Line Items]
Legal fees	$ 115,000
Related party transaction costs		$ 153,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 4,900,000
Unrecognized compensation expense recognition period	2 years 9 months 18 days
2015 Equity Incentive Plan and 2016 Director Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grants | shares	7,885,273
Equity Incentive Plan 2015 and 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value, options	$ 0
Share price (in dollars per share) | $ / shares	$ 0.28

Equity Incentive Plan - Allocat

Equity Incentive Plan - Allocation of Share Based Compensation (Detail) - USD ($)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 540,000	$ 644,000
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	451,000	471,000
Research and development expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total allocated compensation expense	$ 89,000	$ 173,000

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted (Detail)	3 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Summary Of Stock Option Activities [Line Items]
Expected term (in years)	6 years 1 month 6 days
Dividend yield	0%	0%
Minimum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	2.83%	0.28%
Expected volatility	115.36%	97.11%
Expected term (in years)		2 years 8 months 12 days
Maximum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	2.92%	1.01%
Expected volatility	115.39%	105.37%
Expected term (in years)		6 years 1 month 6 days

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Stock Options (Detail)	3 Months Ended
	Jun. 30, 2022 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning | shares	14,504,271
Granted | shares	3,641,300
Cancelled/Forfeited | shares	(892,265)
Outstanding at ending | shares	17,253,306
Options exercisable | shares	9,387,474
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning | $ / shares	$ 2.36
Granted | $ / shares	0.32
Cancelled/Forfeited | $ / shares	5.47
Outstanding at ending | $ / shares	1.77
Options exercisable | $ / shares	$ 2.55

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of Stock Option by Exercise Price Range (Detail) - Exercise Price $0.29 - $8.75 [Member]	3 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Stock Options Outstanding
Range of Exercise Price, Lower Limit	$ 0.29
Range of Exercise Price, Upper Limit	$ 8.75
Number Outstanding | shares	17,253,306
Weighted Average Exercise Price	$ 1.77
Weighted Average Remaining Life (Years)	7 years 6 months
Aggregate Intrinsic Value | $	$ 0
Stock Options Vested
Stock Options Vested | shares	9,387,474
Weighted Average Exercise Price	$ 2.55
Aggregate Intrinsic Value | $	$ 0